TP53 and acute myeloid leukemia: It is of interest that in a preclinical setting, the triple inhibition of MDM2, XPO1, and BCL2 effectively overcomes resistance by reactivating p53, disrupting c-MYC-driven resistance, and preventing stress-adapted VEN resistance in AML [129].